NEWS, VIEWS, & REVIEWS
November 2018 | Volume 17 | Issue 11 | Feature | 1251 | Copyright © 2018
No abstract available
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Cutera Launches truSculpt® iD, Personalized Body Sculpting: The Next Evolution Cutera Inc., a leading provider of laser, light, and other energy-based aesthetic systems for practitioners worldwide, today announces the availability of truSculpt® iD, the next evolution in body sculpting with unique hands-free capability and the ability to treat a full abdomen in as little as 15 minutes. truSculpt iD’s sleek design and comprehensive handpiece options give physicians and other qualified practitioners the flexibility to deliver personalized body sculpting to patients through either a hand-held or hands-free treatment technique in a fraction of the time required by other body sculpting options on the market. This, alongside its unique ability to treat various fat densities and all skin types, highlights the versatility of the truSculpt iD technology. A non-surgical body sculpting system, truSculpt iD uses innovative monopolar radio frequency (RF) technology to selectively target fat and therapeutically heat it until fat cells are slowly removed and excreted through the body naturally. Penetrating deep to treat the entire fat layer from skin to muscle, truSculpt iD is clinically proven for permanent fat cell destruction. With real-time temperature control working to provide consistent results, studies have shown an average fat reduction of 24 percent, with patients seeing improvements 6-12 weeks following the first treatment. “truSculpt iD allows patients to achieve truly tailored results in a significantly shorter time frame, making it a very appealing non-invasive option for permanently eliminating fat cells in stubborn areas,” commented Dr. Anne Chapas, internationally acclaimed dermatologic surgeon and Medical Director of Union Square Laser Dermatology. “With such an efficient technology and the ability to treat multiple body areas simultaneously, we are able to treat more patients in a shorter period of time as a result.” “We are proud to announce the availability of truSculpt iD, supporting our mission to develop powerful technologies that advance the medical aesthetics industry and help clinicians expand their body sculpting practice,” said James Reinstein, President and CEO of Cutera, Inc. “truSculpt iD delivers results regardless of the patient’s shape or body type - allowing physicians to effectively treat those who might not be candidates for other contouring procedures. We believe the truSculpt iD will expand the market with this comfortable, safe, and highly accelerated sculpting procedure.” “Additionally, truSculpt iD further enhances our expanding portfolio of devices which incorporate a disposable element. These new consumables allow us to participate in procedure-based recurring revenue along with our physician customers.”The launch of truSculpt iD comes at a time of significant growth for the industry. Research shows non-surgical fat reduction was the top non-surgical and non-invasive procedure in 2017, with procedures increasing by 24.7 percent. Looking ahead, the body shaping and skin tightening market is expected to expand by 14.5 percent year-over-year.Lumenis Introduces New Laser Hair Removal Solution, SPLENDOR X, at the 2018 American Society of Dermatological Surgery (ASDS) Lumenis LTD, the world’s largest energy-based medical device company for aesthetic, surgical, and ophthalmic applications, excitedly announces its newest launch, SPLENDOR X— the first solid state laser system equipped with the unique BLEND X technology for fast and effective hair removal and skin solutions. The technology was showcased for the first time at the 2018 American Society of Dermatological Surgery – ASDS in Phoenix. SPLENDOR X treats the widest range of hair removal procedures, with BLEND X, bilateral laser emission of Nd: YAG (1064nm) and Alexandrite (755nm) wavelengths, synchronized to fire with adjustable proportions. At 250W output power, SPLENDOR X provides rapid coverage rate combining high fluency, large spot size, and high repetition rate. The unique square spot shape eliminates overlap and hot spots guaranteeing uniform skin coverage. Furthermore, a built-in plume evacuator ensures a smoke free and safer environment.“The SPLENDOR X technology not only allows the use of the laser on all other skin tones, but thanks to its unique BLEND X technology, I’m able to create customized treatment options for patients of all skin types and hair types” said Dr. Suzanne L. Kilmer of Laser and Skin Surgery Center in Northern California. “The two adjustable wavelengths, Nd: YAG and Alexandrite allow me to use the machine to fit treatment requirements to each individual.”The Skin Cancer Foundation Comments on FDA Approval of Libtayo for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma The U.S. Food and Drug Administration (FDA) approved cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) and for patients with advanced local CSCC who are not suitable candidates for surgery or radiation. Cutaneous squamous cell carcinoma is a type of nonmelanoma skin cancer arising from the squamous cells in the epidermis, the skin’s outermost layer. While fewer people develop CSCC than BCC, the most common type of skin cancer, CSCC can be more dangerous. CSCC has a higher risk than BCC of becoming locally advanced or metastatic. Studies have shown that about 1.5 percent of patients with CSCC die of the disease — approximately 15,000 people in the U.S. each year. Cemiplimab was jointly developed by Sanofi and Regeneron under a global collaboration agreement. Regeneron and Sanofi are financial supporters of The Skin Cancer Foundation.